In vitro susceptibility of fosfomycin in uropathogens with emerging resistance in Enterococcus isolates

Sulmaz Reshi; Abha Sharma; Poonam Loomba; Manisha Jain; Tanvi Aggrawal; Bibha Mishra

doi:10.18203/2320-6012.ijrms20242218

Authors

Sulmaz Reshi Department of Microbiology, GB Pant Institute of Medical Education and Research (GIPMER), New Delhi, India
Abha Sharma Department of Microbiology, GB Pant Institute of Medical Education and Research (GIPMER), New Delhi, India
Poonam Loomba Department of Microbiology, GB Pant Institute of Medical Education and Research (GIPMER), New Delhi, India
Manisha Jain Department of Microbiology, GB Pant Institute of Medical Education and Research (GIPMER), New Delhi, India
Tanvi Aggrawal Department of Microbiology, GB Pant Institute of Medical Education and Research (GIPMER), New Delhi, India
Bibha Mishra Department of Microbiology, GB Pant Institute of Medical Education and Research (GIPMER), New Delhi, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20242218

Keywords:

Antimicrobial resistance, Antimicrobial susceptibility testing, Nosocomial infections, Uropathogens

Abstract

Background: Urinary tract infection is a very common clinical entity and are the leading causes of nosocomial infections. The options for antibiotics especially for nosocomial infections are very limited. Fosfomycin a good drug to be used in UTI and is recommend as first line agents for acute uncomplicated UTIs. The emergence of resistance to fosfomycin is a concern. Limited resistance data for fosfomycin is available from India. This study was conducted in order to monitor the trends of resistance to fosfomycin in E coli and Enterococcus faecalis causing UTI.

Methods: Urine samples received in the laboratory from all patients were included in the study. Microscopy of uncentrifuged urine sample was done. Culture and sensitivity was done as per the CLSI guidelines. Susceptibility testing of the isolates to fosfomycin was performed interpretation done as per CLSI.

Results: Total 150 isolates were taken for the study which included 100 isolates of E. coli and 50 isolates of Enterococcus faecalis. None of the E. coli isolates were resistant to fosfomycin and 82.0% of the isolates were found to be sensitive to nitrofurantoin. None of the Enterococcus faecalis isolates were resistant to linezolid. The percentage susceptibility was 52 % and 70 % for nitrofurantoin and fosfomycin respectively.

Conclusions: The increasing resistance to fosfomycin is a matter of concern. An increased fosfomycin resistance rate in E. faecalis was observed. Performing antimicrobial susceptibility testing should be the most important criteria before starting the antibiotic to avoid undue usage and more such studies need to be conducted.

Metrics

Metrics Loading ...

References

Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 2009;53(10):4508-10.

Chooramani G, Jain B, Chauhan PS. Prevalence and antimicrobial sensitivity pattern of bacteria causing urinary tract infection; study of a tertiary care hospital in North India. Clin Epidemiol Global Health. 2022;8(3):890-3.

Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol. 2016;2016(1):2082693.

Aprile A, Scalia G, Stefani S, Mezzatesta ML. In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae. J Glob Antimicrob Resist. 2020;23:286-289.

Ou LB, Nadeau L. Fosfomycin susceptibility in multidrug-resistant enterobacteriaceae species and vancomycin-resistant enterococci urinary isolates. Can J Hosp Pharm. 2017;70(5):368-74.

Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321-47.

M100 Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. Clinical and Laboratory Standards Institute; 2021:45, 75.

Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):732-9.

Diez-Aguilar M, Canton R. New microbiological aspects of fosfomycin. Rev Esp Quimioter. 2019;32(Suppl 1):8-18.

Kumar D, Das A, Purbey MK, Gupta N, Nath G. Susceptibility of uropathogenic multidrug-resistant Escherichia coli to Fosfomycin. J Acad Clin Microbiol. 2017;19(2):101-4.

Behera B, Mohanty S, Sahu S, Praharaj AK. In vitro activity of fosfomycin against multidrug-resistant urinary and nonurinary gram-negative isolates. Indian J Crit Care Med. 2018;22(7):533-6.

Hareendranath G, Mukundan A, Kunjappan SP. Fosfomycin susceptibility in multidrug resistant urinary Escherichia coli isolates. J Evolution Med Dent Sci. 2021;10(07):414-8.

Batra P, Abrol AK, Gupta S, Pushpan P, Kumar R. Susceptibility pattern of oral antimicrobials in uncomplicated UTI: Does fosfomycin still stand effective? J Family Med Prim Care. 2020;9(2):850-3.

Silver LL. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med. 2017;7(2):a025262.

Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010;65(11):2459-63.

Ríos E, Del Carmen López Diaz M, Culebras E, Rodríguez-Avial I, Rodríguez-Avial C. Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli. Med Microbiol Immunol. 2022;211(5-6):269-72.

Fajfr M, Louda M, Paterová P, Ryšková L, Pacovský J, Košina J, et al. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study. BMC Urol. 2017;17(1):33.

Abbott IJ, van Gorp E, van der Meijden A, Wijma RA, Meletiadis J, Roberts JA, Mouton JW, Peleg AY. Oral fosfomycin treatment for enterococcal urinary tract infections in a dynamic in vitro model. Antimicrob Agents Chemother. 2020;64(6):e00342-20.

Kraszewska Z, Skowron K, Kwiecińska-Piróg J, Grudlewska-Buda K, Przekwas J, Wiktorczyk-Kapischke N, et al. Antibiotic resistance of enterococcus spp. isolated from the urine of patients hospitalized in the university hospital in North-Central Poland, 2016-2021. Antibiotics (Basel). 2022;11(12):1749.

Chakraborty A, Pal NK, Sarkar S, Gupta MS. Antibiotic resistance pattern of Enterococci isolates from nosocomial infections in a tertiary care hospital in Eastern India. J Nat Sci Biol Med. 2015;6(2):394-7.

Kiruthiga A, Padmavathy K, Shabana P, Gnanadesikan S, Malaiyan J, Shoba T. Fosfomycin susceptibility among urinary enterococcus faecalis with high level aminoglycoside and glycopeptide resistant phenotypes. Ind J Publ Heal Res Develop. 2019;10(12):970-4.

Sharifi Y, Hasani A, Ghotaslou R, Naghili B, Aghazadeh M, Milani M, et al. Virulence and antimicrobial resistance in enterococci isolated from urinary tract infections. Advan Pharma Bull. 2013;3(1):197.

Sengupta M, Sarkar R, Sarkar S, Ghosh S, Banerjee P, Sengupta M. Excellent fosfomycin and linezolid susceptibility among multidrug resistant urinary Enterococcus isolates in Eastern India. World J Advan Res Revi. 2020;7(02):331-5.

Allerberger F, Klare I. In-vitro activity of Fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother. 1999;43(2):211-217.

Codelia-Anjum A, Lerner LB, Elterman D, Zorn KC, Bhojani N, Chughtai B. Enterococcal urinary tract infections: a review of the pathogenicity, epidemiology, and treatment. Antibiotics. 2023;12(4):778.

Nightingale J. Clinical limitations of in vitro testing of microorganism susceptibility. Am J Hosp Pharm. 1987;44(1):131-7.